Middle East and Africa Cancer Therapeutics Market Report (2021–2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The cancer therapeutics market size is expected to reach US$ 9,078.95 million by 2031 from US$ 4,503.08 million in 2024. The market is estimated to record a CAGR of 10.6% from 2025 to 2031.

Executive Summary and Middle East and Africa Cancer Therapeutics Market Analysis:

The Middle East and Africa (MEA) cancer therapeutics market is set to experience long-term and high-growth development over the next decade. This is being driven by a number of convergent drivers, including technological advancement, targeted investments in healthcare facilities, and a shift toward personalized medicine. Governments across the MEA region are allocating larger portions of their budgets to healthcare, reflecting a growing commitment to tackling non-communicable diseases like cancer. For instance, Saudi Arabia's Vision 2030 includes robust plans to expand oncology centers and equip hospitals with cutting-edge medical technologies. The market for cancer drugs in Middle East and Africa is poised for further growth through both local production and international partnerships.

Middle East and Africa Cancer Therapeutics Market Segmentation Analysis:

Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.

By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.

Middle East and Africa Cancer Therapeutics Market Outlook

The incidence of cancer in the Middle East and Africa (MEA) is increasing at a high rate, posing a crucial public health issue for the region. Based on the report from the World Health Organization (WHO) and the Global Cancer Observatory, the incidence and death rates due to cancer in MEA nations have been on an upward trend over the last decade. This is being driven by a number of interconnected factors such as population growth, aging population, urbanization, and lifestyle change. According to the WHO, in 2022, the UAE had an estimated 5,526 new cancer cases and 2,283 deaths due to cancer. The age-standardized incidence rate was 107.8 per 100,000 people. Breast cancer was the most frequent among women, making up 39.1% of cancers, followed by thyroid cancer (11.5%) and colorectal cancer (7.0%). Among males, prostate cancer (11.9%), colorectal cancer (13.3%), and bladder cancer (7.3%) were the most common. The crude incidence rate was higher in females (108.7 per 100,000) than in males (39.5 per 100,000).

Middle East and Africa Cancer Therapeutics Market Country Insights

Based on region, the Middle East and Africa cancer therapeutics market is further segmented into UAE, Saudi Arabia, Kuwait, Bahrain, Qatar, Egypt, South Africa, Algeria, Nigeria, Oman, and Turkey. The South Africa held the largest share in 2024.

According to the World Health Organization (WHO) and the Global Cancer Observatory, South Africa had 111,321 number of new cases of South Africa in 2022 and 64,547 number of deaths due to cancer. The WHO also estimated that there are 282,418 number of prevalent cases (5-year).

South Africa's cancer therapeutics market is on a consistent path of expansion, driven by a convergence of medical advances, strategic investment in healthcare, and growing emphasis on tailored treatment approaches. With increasing cancer incidence in the country, urbanization, and lifestyle issues like unhealthy diet, smoking, and sedentary lifestyle, the demand for effective cancer treatments is on the rise.

Technological innovation has been pivotal to revolutionizing cancer treatment. South Africa has started incorporating cutting-edge treatments like immunotherapy, targeted therapies, and genomic medicine into the healthcare system. Immunotherapies, for instance, monoclonal antibodies and checkpoint inhibitors, are picking up, especially in the management of difficult-to-treat cancers like melanoma and lung cancer. Diagnostic technologies like molecular profiling and next-generation sequencing (NGS) are facilitating earlier and better detection, critical to the success of personalized medicine.

Government and private investments are also increasing access to cancer treatment facilities. Government-run oncology centers, radiology services, and research projects are being financed through public-private partnerships, with a concentration in urban centers like Johannesburg and Cape Town. This advancement is not distributed evenly.

Middle East and Africa Cancer Therapeutics Market Company Profiles

Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These players adopt strategies such as expansion, product innovation, and mergers and acquisitions to stay competitive in the market and offer innovative products to their consumers.

Middle East and Africa Cancer Therapeutics Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

Company websites, annual reports, financial statements, broker analyses, and investor presentations Industry trade journals and other relevant publications Government documents, statistical databases, and market reports News articles, press releases, and webcasts specific to companies operating in the marketNote:All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:

Refine findings from secondary research Enhance the expertise and market understanding of the analysis team Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:

Industry stakeholders:

Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise Key Sources Referred:

World Health Organization (WHO) Macmillan Cancer Support Global Cancer Observatory Eurostat Danish Cancer Society European Cancer Information System (ECIS)